북미 뎅기열 치료 시장 – 2028년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

북미 뎅기열 치료 시장 – 2028년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Feb 2021
  • North America
  • 350 Pages
  • 테이블 수: 99
  • 그림 수: 52

North America Dengue Treatment Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2021 –2028
Diagram 시장 규모(기준 연도)
USD 71.42 Million
Diagram 시장 규모(예측 연도)
USD 387.13 Million
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

북미 뎅기열 치료 시장, 균주별(DENV-1, DENV-2, DENV-3, DENV-4, 기타), 전염(모기-사람 전염 및 모자 전염), 유형(약물, 지지 치료, 예방 접종 및 기타), 심각도(간단하고 심각), 투여 경로(경구 및 비경구), 구매 방식(처방 및 일반 의약품(OTC)), 최종 사용자(병원, 전문 병원, 가정 의료 및 기타), 유통 채널(병원 약국, 소매 약국, 온라인 약국 및 기타), 국가(미국, 캐나다 및 멕시코) 산업 동향 및 2028년까지의 예측

북미 뎅기열 치료 시장시장 분석 및 통찰력: 북미 뎅기열 치료 시장

뎅기열 치료 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 23.9%의 CAGR로 성장하고 있으며 2028년까지 7,142만 달러에서 3억 8,713만 달러에 도달할 것으로 예상한다고 분석했습니다. 시장 참여자들의 전략적 이니셔티브와 뎅기열 치료를 위한 대량 예방 접종 프로그램의 출현은 뎅기열 치료 시장의 주요 동인이 될 가능성이 높습니다.

뎅기열 은 모기에 의해 전파되는 바이러스성 질병으로 최근 몇 년 동안 WHO(세계보건기구)의 모든 지역에서 빠르게 확산되었습니다. 뎅기열 바이러스는 주로 Aedes Aegyptus 속의 암컷 모기에 의해 전파되고, 덜한 정도로 Ae. albopictus에 의해 전파됩니다. 이러한 매개 모기에 의해 전파되는 질병에는 치쿤구냐, 황열병 및 지카 바이러스가 있습니다. 뎅기열은 열대 지방에서 만연하며, 강수량, 기온 , 상대 습도 및 지역적 위험 변동성을 지닌 계획되지 않은 급속한 도시화로 인해 발생합니다.

통제된 조치에도 불구하고, 뎅기열 발병률의 세계적 증가와 함께 지역적 발병 빈도 증가 및 이집트숲모기 종의 번성 가능성은 뎅기열 치료 옵션의 소비 증가로 이어지고 뎅기열 치료 시장의 원동력이 될 것으로 예상됩니다. 뎅기열 치료 비용은 위에 나열된 대로 더 높고 다중 장기 부전과 같은 뎅기열과 관련된 합병증이 더 많으면 감염된 사람이 뎅기열 치료에 대한 적절한 치료를 피하게 되어 치료 총 비용이 증가할 수 있으므로 뎅기열 치료 시장의 제약 요인으로 작용할 수 있습니다. 뎅기열은 전통적으로 혈청학적 검사로 진단할 수 있지만 이제 기술이 업그레이드되면서 바이러스를 감지하는 다양한 진행 중 및 개발된 방법이 있어 뎅기열 치료 시장에 기회가 생길 것입니다. 뎅기열은 해열제 및 일부 항생제와 같은 비특이적 약물을 사용하는 벡터 매개 질병이지만 전 세계의 다양한 정부 기관에서 취한 예방 조치와 이니셔티브는 뎅기열 치료 시장에 도전이 될 것으로 예상됩니다.

뎅기열 치료 시장 보고서는 시장 점유율, 새로운 개발, 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.

북미 뎅기열 치료 시장북미 뎅기열 치료 시장 범위 및 시장 규모

뎅기열 치료 시장은 균주, 전염, 유형, 심각도, 투여 경로, 구매 방식, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 적용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

  • 균주에 따라 뎅기열 치료 시장은 DENV-1, DENV-2, DENV-3, DENV-4, 기타로 세분화됩니다. 2021년에는 DENV-2 세그먼트가 시장을 지배하고 있는데, 이 균주는 유병률이 높아 뎅기열 감염 사례가 더 많기 때문입니다. 뎅기는 다른 균주로도 발생할 수 있지만 가장 우세한 높은 임상적 합병증은 DENV-2에서 나타납니다.
  • 전염을 기준으로 뎅기열 치료 시장은 모기에서 사람으로 전염되는 것과 모자에서 아이로 전염되는 것으로 구분됩니다. 2021년에는 모기에서 사람으로 전염되는 세그먼트가 시장을 지배하고 있는데, 모기가 다양한 바이러스 균주에 대한 뎅기열 전염의 주요 매개체이기 때문입니다. 모기가 감염된 사람을 물면 그 사람도 감염되어 혈액에서 바이러스를 얻고, 다시 다른 사람을 물면 그 사람에게 바이러스가 전염됩니다. 이것이 모기에서 사람으로 전염되는 것이 시장을 지배하는 이유입니다.
  • 유형에 따라 뎅기열 치료 시장은 약물 , 지지 치료 , 예방 접종 및 기타로 세분화됩니다. 2021년에는 약물 부문이 시장을 지배하고 있는데, 뎅기열 치료에 사용되는 다양한 약물이 매우 오랫동안 뎅기열 관리에 사용되고 있기 때문입니다.
  • 심각도에 따라 뎅기열 치료 시장은 단순 및 중증으로 세분화됩니다. 2021년 단순 세그먼트가 시장을 지배하고 있으며, 단순 뎅기열에서 중증 뎅기열로의 전환율은 5% 미만이며, 이는 단순 세그먼트가 뎅기열 치료 시장을 지배하는 가장 중요한 이유입니다.
  • 투여 경로에 따라 뎅기열 치료 시장은 경구비경구로 세분화됩니다 . 2021년에는 경구 세그먼트가 시장을 지배하고 있는데, 뎅기열 증상을 치료하기 위해 복용하는 대부분의 약물이 통증 관리 및 발열 관리를 위해 경구로 복용되기 때문입니다.
  • 구매 방식에 따라 뎅기열 치료 시장은 처방 과 일반 의약품(OTC)으로 세분화됩니다. 2021년에는 처방 부문이 시장을 지배하고 있는데, 이는 환자가 뎅기 바이러스에 감염되었다는 확인 후 의사가 약물과 지지 요법을 처방하고 치료 옵션은 항생제와 일반적으로 처방 약물로만 제공되지 않는 기타 약물로 구성되기 때문입니다.
  • 최종 사용자를 기준으로 뎅기열 치료 시장은 병원 , 전문 병원, 가정 의료 및 기타로 세분화됩니다. 2021년에는 가정 의료 부문이 시장을 지배하고 있는데, 진단 후 진통제 및 해열제와 같은 약물을 사용하여 뎅기열 증상을 집에서 관리할 수 있기 때문입니다.
  • 유통 채널을 기준으로 뎅기열 치료 시장은 병원 약국, 소매 약국, 온라인 약국 등으로 세분화됩니다. 2021년에는 소매 약국 부문이 시장을 지배하고 있는데, 뎅기열에 대한 적절한 진단 후 감염 치료 주기의 전체 기간 동안 환자의 처방전 대부분이 소매 약국에서 작성되기 때문입니다.

뎅기열 치료 시장 국가 수준 분석

위에 언급된 대로 국가, 균주, 전염성, 유형, 심각도, 투여 경로, 구매 방법, 최종 사용자 및 유통 채널별로 뎅기열 치료 시장을 분석하고 시장 규모 정보를 제공합니다.

뎅기열 치료 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.

미국은 제약 및 생명공학 분야의 연구개발 활동 확대와 아웃소싱 서비스 확대에 중점을 두고 있어 북미 뎅기열 치료 시장을 주도할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

도시 지역에서의 뎅기열 치료의 필요성과 시장 참여자들의 전략적 이니셔티브는 뎅기열 치료 시장 참여자들에게 새로운 기회를 창출하고 있습니다.

뎅기열 치료 시장은 또한 뎅기열 치료 판매, 뎅기열 치료 발전의 영향, 뎅기열 치료 시장에 대한 지원과 함께 규제 시나리오의 변화와 함께 특정 산업의 모든 국가 성장에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 뎅기열 치료 시장 점유율 분석

뎅기열 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선입니다. 제공된 위의 데이터 포인트는 뎅기열 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.

뎅기열 치료제를 제공하는 주요 기업으로는 Aurobindo Pharma, Perrigo Company plc, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Fresenius Kabi USA(Fresenius SE & Co. KGaA의 자회사), Baxter, Vitric Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd.의 자회사), GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Sanofi, EMERGEX VACCINES 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.

시장 참여자들의 협력, 합작투자 및 기타 전략은 뎅기열 치료 시장에서 회사 시장을 강화하고 있으며, 이를 통해 기업은 뎅기열 치료 시장에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF NORTH AMERICA DENGUE TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 STRAINS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

5 PIPELINE ANALYSIS

6 NORTH AMERICA DENGUE TREATMENT MARKET: REGULATIONS

6.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT

6.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT

6.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK

6.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE

6.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

7 CLINICAL STUDIES FOR DENGUE TREATMENT PRODUCTS.

7.1 SYNTHETIC DRUGS

7.2 BIOMARKER

7.3 DIRECT ACTING ANTIVIRAL DRUGS

8 EPIDEMIOLOGY

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 INCREASING INCIDENCE IN DENGUE CASES

9.1.2 ADVENT OF VACCINATION PROGRAMS

9.1.3 INCREASE IN RESEARCH AND DEVELOPMENT FUNDING

9.1.4 ROLE OF IGM AND IGG ANTIBODIES IN DENGUE

9.1.5 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES

9.2 RESTRAINTS

9.2.1 HIGH COST OF TREATMENT

9.2.2 DEARTH AWARENESS ABOUT THE SYMPTOMS OF DENGUE

9.2.3 LACK OR INSUFFICIENT HEALTHCARE INFRASTRUCTURE

9.3 OPPORTUNITIES

9.3.1 NEED FOR DENGUE TREATMENT IN URBAN AREAS

9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

9.3.3 TECHNOLOGICAL ADVANCEMENT IN DENGUE VIRUS DETECTION

9.3.4 INCREASE IN NORTH AMERICA TRAVEL AND RELATION WITH DENGUE

9.4 CHALLENGES

9.4.1 PRESENCE OF PREVENTIVE MEASURES FOR DENGUE AND IT’S SPREAD

9.4.2 CHALLENGES IN DETECTION ASSAY FOR DENGUE

9.4.3 ALTERNATIVES FOR DENGUE TREATMENT

10 IMPACT OF COVID-19 ON NORTH AMERICA DENGUE TREATMENT MARKET

10.1 IMPACT ON PRICE

10.2 IMPACT ON DEMAND

10.3 IMPACT ON SUPPLY CHAIN

10.4 STRATEGIC DECISION BY MANUFACTURERS

10.5 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19

10.6 CONCLUSION

11 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS

11.1 OVERVIEW

11.2 DENV-3

11.3 DENV-2

11.4 DENV-1

11.5 DENV-4

11.6 OTHERS

12 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION

12.1 OVERVIEW

12.2 MOSQUITO-TO-HUMAN TRANSMISSION

12.3 MOTHER-TO-CHILD- TRANSMISSION

12.4 OTHERS

13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE

13.1 OVERVIEW

13.2 MEDICATION

13.2.1 ACETAMINOPHEN

13.2.2 ANTIBIOTICS

13.2.2.1 Ciprofloxacin

13.2.2.2 Chloramphenicol

13.2.2.3 Ceftriaxone

13.2.2.4 Ofloxacin

13.2.2.5 Others

13.2.3 IMMUNOGLOBULINS

13.2.4 CORTICOSTEROIDS

13.2.5 ANTI-VIRALS

13.2.6 OTHERS

13.3 SUPPORTIVE CARE

13.4 VACCINATION

13.4.1 DENGVAXIA (CYD-TDV)

13.4.2 DENVAX (TAK-003)

13.4.3 TETRAVAX-DV

13.4.4 TDEN PIV

13.5 OTHERS

14 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY

14.1 OVERVIEW

14.2 UNCOMPLICATED

14.3 SEVERE

15 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

15.1 OVERVIEW

15.2 ORAL

15.2.1 TABLET

15.2.2 CAPSULES

15.2.3 OTHERS

15.3 PARENTERAL

15.3.1 INTRAVENOUS

15.3.2 SUBCUTANEOUS

15.3.3 OTHERS

16 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

16.1 OVERVIEW

16.2 PRESCRIPTION

16.3 OVER THE COUNTER (OTC)

17 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER

17.1 OVERVIEW

17.2 HOME HEALTHCARE

17.3 HOSPITALS

17.4 SPECIALTY CLINICS

17.5 OTHERS

18 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

18.1 OVERVIEW

18.2 RETAIL PHARMACIES

18.3 HOSPITAL PHARMACY

18.4 ONLINE PHARMACY

18.5 OTHERS

19 NORTH AMERICA DENGUE TREATMENT MARKET, BY GEOGRAPHY

19.1 NORTH AMERICA

19.1.1 MEXICO

19.1.2 U.S.

19.1.3 CANADA

20 NORTH AMERICA DENGUE TREATMENT MARKET, COMPANY LANDSCAPE

20.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

21 SWOT ANALYSIS

22 COMPANY PROFILE

22.1 VIATRIS INC.

22.1.1 COMPANY SNAPSHOT

22.1.2 COMPANY SHARE ANALYSIS

22.1.3 PRODUCT PORTFOLIO

22.1.4 RECENT DEVELOPMENT

22.2 PFIZER INC.

22.2.1 COMPANY SNAPSHOT

22.2.2 REVENUE ANALYSIS

22.2.3 COMPANY SHARE ANALYSIS

22.2.4 PRODUCT PORTFOLIO

22.2.5 RECENT DEVELOPMENTS

22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)

22.3.1 COMPANY SNAPSHOT

22.3.2 REVENUE ANALYSIS

22.3.3 COMPANY SHARE ANALYSIS

22.3.4 PRODUCT PORTFOLIO

22.3.5 RECENT DEVELOPMENT

22.4 PERRIGO COMPANY PLC

22.4.1 COMPANY SNAPSHOT

22.4.2 REVENUE ANALYSIS

22.4.3 COMPANY SHARE ANALYSIS

22.4.4 PRODUCT PORTFOLIO

22.4.5 RECENT DEVELOPMENTS

22.5 GLAXOSMITHKLINE PLC

22.5.1 COMPANY SNAPSHOT

22.5.2 REVENUE ANALYSIS

22.5.3 COMPANY SHARE ANALYSIS

22.5.4 PRODUCT PORTFOLIO

22.5.5 RECENT DEVELOPMENT

22.6 DR. REDDY’S LABORATORIES LTD.

22.6.1 COMPANY SNAPSHOT

22.6.2 REVENUE ANALYSIS

22.6.3 PRODUCT PORTFOLIO

22.6.4 RECENT DEVELOPMENT

22.7 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)

22.7.1 COMPANY SNAPSHOT

22.7.2 REVENUE ANALYSIS

22.7.3 PRODUCT PORTFOLIO

22.7.4 RECENT DEVELOPMENTS

22.8 SUN PHARMACEUTICAL INDUSTRIES LTD.

22.8.1 COMPANY SNAPSHOT

22.8.2 REVENUE ANALYSIS

22.8.3 PRODUCT PORTFOLIO

22.8.4 RECENT DEVELOPMENTS

22.9 ABIVAX

22.9.1 COMPANY SNAPSHOT

22.9.2 PRODUCT PORTFOLIO

22.9.3 RECENT DEVELOPMENTS

22.1 AUROBINDO PHARMA

22.10.1 COMPANY SNAPSHOT

22.10.2 REVENUE ANALYSIS

22.10.3 PRODUCT PORTFOLIO

22.10.4 RECENT DEVELOPMENTS

22.11 BAXTER

22.11.1 COMPANY SNAPSHOT

22.11.2 REVENUE ANALYSIS

22.11.3 PRODUCT PORTFOLIO

22.11.4 RECENT DEVELOPMENT

22.12 EMERGEX VACCINES

22.12.1 COMPANY SNAPSHOT

22.12.2 PRODUCT PORTFOLIO

22.12.3 RECENT DEVELOPMENTS

22.13 HIKMA PHARMACEUTICALS PLC

22.13.1 COMPANY SNAPSHOT

22.13.2 REVENUE ANALYSIS

22.13.3 PRODUCT PORTFOLIO

22.13.4 RECENT DEVELOPMENT

22.14 SANOFI

22.14.1 COMPANY SNAPSHOT

22.14.2 REVENUE ANALYSIS

22.14.3 PRODUCT PORTFOLIO

22.14.4 RECENT DEVELOPMENTS

22.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED

22.15.1 COMPANY SNAPSHOT

22.15.2 REVENUE ANALYSIS

22.15.3 PRODUCT PORTFOLIO

22.15.4 RECENT DEVELOPMENTS

23 QUESTIONNAIRE

24 RELATED REPORTS

표 목록

LIST OF TABLES

TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION

TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

그림 목록

LIST OF TABLES

TABLE 1 NORTH AMERICA DENGUE TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION

TABLE 3 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 2019-2028 (USD MILLION)

TABLE 4 NORTH AMERICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 NORTH AMERICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA MOSQUITO-TO-HUMAN TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA MOTHER-TO-CHILD TRANSMISSION IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 16 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 18 NORTH AMERICA SUPPORTIVE CARE IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION

TABLE 19 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 20 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 21 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION), BY REGION

TABLE 22 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 2019-2028 (USD MILLION)

TABLE 23 NORTH AMERICA UNCOMPLICATED IN DENGUE TREATMENT MARKET, BY REGION 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA SEVERE IN DENGUE TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 27 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 28 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION), BY REGION

TABLE 29 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 30 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 32 NORTH AMERICA OVER THE COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION), BY REGION

TABLE 33 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 NORTH AMERICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 35 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 36 NORTH AMERICA SPECIALTY CLINICS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 37 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION), BY REGION

TABLE 38 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA DIRECT TENDER IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 41 NORTH AMERICA ONLINE PHARMACY IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 42 NORTH AMERICA HOSPITALS IN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION), BY REGION

TABLE 43 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 56 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 57 NORTH AMERICADENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 58 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 59 MEXICO DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 60 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 61 MEXICO MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 62 MEXICO ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 63 MEXICO OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 64 MEXICO VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 66 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 67 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 68 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 69 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 70 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 71 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 72 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 73 U.S. DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 74 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 75 U.S. MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 76 U.S. ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 U.S. OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 78 U.S. VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 79 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 80 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 U.S. ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 83 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 84 U.S. DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 85 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 86 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2019-2028 (USD MILLION)

TABLE 87 CANADA DENGUE TREATMENT MARKET, BY TRANSMISSION, 2019-2028 (USD MILLION)

TABLE 88 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 89 CANADA MEDICATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 90 CANADA ANTIBIOTICS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 91 CANADA OTHERS IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 92 CANADA VACCINATION IN DENGUE TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 93 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

TABLE 94 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 95 CANADA ORAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 96 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 97 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2019-2028 (USD MILLION)

TABLE 98 CANADA DENGUE TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 99 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

LIST OF FIGURES

FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET END USER GRID

FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE NORTH AMERICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA DENGUE TREATMENT MARKET

FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020

FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)

FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)

FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE

FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020

FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)

FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)

FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE

FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020

FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020

FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)

FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).

FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE

FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)

FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020

FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)

FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)

FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020

FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)

FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)

FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

 LIST OF FIGURES

FIGURE 1 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DENGUE TREATMENT MARKET : DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DENGUE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DENGUE TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DENGUE TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DENGUE TREATMENT MARKET: MARKET END USER GRID

FIGURE 10 NORTH AMERICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 NORTH AMERICA DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 12 INCREASING INCIDENCE OF DENGUE CASES AND ADVENT OF VACCINATION PROGRAMS ARE DRIVING THE NORTH AMERICA DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 FUNGAL DENGUE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DENGUE TREATMENT MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF NORTH AMERICA DENGUE TREATMENT MARKET

FIGURE 15 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020

FIGURE 16 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, 2020-2028 (USD MILLION)

FIGURE 17 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2021-2028)

FIGURE 18 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE

FIGURE 19 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, 2020

FIGURE 20 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION 2020-2028 (USD MILLION)

FIGURE 21 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, CAGR (2021-2028)

FIGURE 22 NORTH AMERICA DENGUE TREATMENT MARKET: BY TRANSMISSION, LIFELINE CURVE

FIGURE 23 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020

FIGURE 24 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 25 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2020-2028)

FIGURE 26 NORTH AMERICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 27 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, 2020

FIGURE 28 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY , 2020-2028 (USD MILLION)

FIGURE 29 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2021-2028).

FIGURE 30 NORTH AMERICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE

FIGURE 31 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 32 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)

FIGURE 33 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)

FIGURE 34 NORTH AMERICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020

FIGURE 36 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2020-2028 (USD MILLION)

FIGURE 37 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2020-2028)

FIGURE 38 NORTH AMERICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 39 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020

FIGURE 40 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 41 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2020-2028)

FIGURE 42 NORTH AMERICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 44 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 45 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 46 NORTH AMERICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 NORTH AMERICA DENGUE TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 48 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 49 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 50 NORTH AMERICA DENGUE TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 51 NORTH AMERICA DENGUE TREATMENT MARKET: BY STRAINS (2021-2028)

FIGURE 52 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2020 (%)

 

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The market is segmented based on , By Strains (DENV-1, DENV-2, DENV-3, DENV-4, Others), Transmission (Mosquito-to-Human Transmission and Mother-to-Child Transmission), Type (Medication, Supportive Care, Vaccination and Others), Severity (Uncomplicated and Severe), Route of Administration (Oral and Parenteral), Mode of Purchase (Prescription and Over the Counter (OTC)), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others), Country (U.S., Canada & Mexico) Industry Trends and Forecast to 2028 .
The North America Dengue Treatment Market size was valued at USD 71.42 USD Million in 2020.
The North America Dengue Treatment Market is projected to grow at a CAGR of 23.9% during the forecast period of 2021 to 2028.